PCVX insider sales reported on Form 144

PCVX Form 144 notice reports insider sales of Common Stock by Elvia Cowan.

Rhea-AI Filing Summary

PCVX Form 144 notice reports insider sales of Common Stock by Elvia Cowan. The filing lists a sale of 11,623 shares on 12/23/2025 for $556,971.85 and a sale of 2,500 shares on 03/11/2026 for $146,481.75.

The notice also records recent RSU vesting entries issued by the company on 02/28/2026 (432 shares), 03/02/2026 (580 shares) and 03/07/2026 (880 shares). The report is a near-term disclosure of transactions and issuer-issued vesting events.

Insights

Securities Compliance Analyst

Form 144 discloses two sales by Elvia Cowan and several RSU vesting events.

Form 144 lists a 12/23/2025 disposition of 11,623 shares for $556,971.85 and a 03/11/2026 disposition of 2,500 shares for $146,481.75. These entries are routine disclosure notices required when restricted or control securities are sold under Regulation 144.

The filing also enumerates issuer-recorded RSU vesting on 02/28/2026, 03/02/2026, and 03/07/2026 totaling 1,892 shares. Cash‑flow treatment and any trading plan reference are not provided in the excerpt; subsequent filings or footnotes would clarify whether sales were open‑market or pursuant to other arrangements.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What sales does the PCVX Form 144 report show?

The Form 144 shows sales by Elvia Cowan of 11,623 shares on 12/23/2025 for $556,971.85 and 2,500 shares on 03/11/2026 for $146,481.75. These are the reported dispositions listed in the excerpt.

Does the filing show any RSU vesting at PCVX?

Yes. The excerpt lists RSU vesting by the issuer on 02/28/2026 (432), 03/02/2026 (580) and 03/07/2026 (880), totaling 1,892 shares in the period shown.

Who is the reporting person in the Form 144 excerpt for PCVX?

The reporting person named is Elvia Cowan, with an address in San Carlos, CA. The excerpt attributes the two listed share dispositions to that individual.

Does the excerpt specify how the sales were executed or who received proceeds?

No. The excerpt lists sale dates, share counts, and gross amounts but does not state execution method or which party received proceeds; that detail is not in the provided text.

Are the RSU vesting amounts included among the sold shares in this Form 144?

The excerpt separately lists RSU vesting amounts and the reported dispositions; it does not state that vested RSUs were sold. The relationship between vesting and the sales is not specified in the provided excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/17/2026 - 04:16 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001960048
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Vaxcyte, Inc.
SEC File Number	001-39323
Address of Issuer	825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CALIFORNIA 94070
Phone	650-837-0111
Name of Person for Whose Account the Securities are To Be Sold	Cowan Elvia
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc 11 Madison Ave 4th Floor New York NY 10010	1892	105743.88	143920361	03/17/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/02/2026	RSU Vesting	Issuer			580	03/02/2026	NA
Common	02/28/2026	RSU Vesting	Issuer			432	02/28/2026	NA
Common	03/07/2026	RSU Vesting	Issuer			880	03/07/2026	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Elvia Cowan 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070	Common	03/11/2026	2500	146481.75
Elvia Cowan 825 INDUSTRIAL ROAD STE. 300 San Carlos CA 94070	Common	12/23/2025	11623	556971.85

144: Remarks and Signature

Remarks
Date of Notice	03/17/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/08/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc, as attorney-in-fact for Elvia Cowan
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)